国药一致(000028) - 2024 Q3 - 季度业绩

Financial Performance - In the first three quarters of 2024, the company achieved total operating revenue of CNY 56.47 billion, a decrease of 0.21% year-on-year[1]. - The net profit attributable to shareholders for the first three quarters of 2024 was CNY 1.07 billion, down 10.43% year-on-year, with basic earnings per share decreasing by 10.75%[1][3]. - In Q3 2024, the company reported total operating revenue of CNY 18.68 billion, an increase of 2.65% year-on-year, while net profit attributable to shareholders was CNY 322.05 million, a decrease of 10.39% year-on-year[2][3]. - The distribution segment generated operating revenue of CNY 40.84 billion in the first three quarters of 2024, up 3.20% year-on-year, but net profit decreased by 0.91%[3]. - The retail segment, operating under "China National Pharmaceutical Group Co., Ltd.", reported operating revenue of CNY 16.40 billion, down 7.47% year-on-year, with a net loss of CNY 39 million, a decline of 110.36%[3]. Asset and Equity - The company’s total assets increased by 9.27% to CNY 51.98 billion compared to the beginning of the reporting period[1]. - The weighted average return on equity decreased by 1.19 percentage points to 5.99% in the first three quarters of 2024[1]. Strategic Goals - The company aims to enhance the quality and efficiency of its core business while adapting to external environmental changes and operational challenges[4].